Hangzhou, Zhejiang, China, September 16, 2025 – Doer Biologics Co., Ltd. (“Doer Bio”), a clinical-stage biopharmaceutical company majority-owned by Huadong Medicine, focused on developing innovative biologic therapies for metabolic diseases and cancer, today announced that the Phase 2 clinical study results (“DR10624-201 Study”) of its internally developed, first-in-class (FIC) long-acting tri-specific agonist targeting Fibroblast Growth Factor 21 Receptor (FGF21R), Glucagon Receptor (GCGR), and Glucagon-Like Peptide-1 Receptor (GLP-1R), for the treatment of severe hypertriglyceridemia (SHTG), have been selected for presentation in the Late-Breaking Science (LBS) session at the American Heart Association (AHA) Scientific Sessions 2025. It has also been designated as one of the "Groundbreaking Trials in Cardiometabolic Therapeutics."
Particularly noteworthy is that the DR10624-201 Study results will be presented as the Opening Presentation in the Main Event of AHA 2025. This prominent placement underscores the high level of recognition by the international scientific community regarding the scientific value and clinical potential of DR10624.
Professor Jianping Li, Principal Investigator of the study, Vice President of Peking University First Hospital and Director of its Cardiovascular Research Institute, will deliver this Opening Presentation, unveiling the DR10624-201 Study’s clinical data globally for the first time. This marks the first time a scholar from China's cardiology field has presented the Opening LBS Presentation at the AHA Annual Meeting, signifying a historic breakthrough for China in cardiovascular and lipid metabolism clinical research, as well as in the development of innovative therapies for cardiovascular diseases.
The AHA Scientific Sessions 2025 will be held from November 7th to 10th, 2025, in New Orleans, Louisiana, USA. Founded in 1924, the American Heart Association (AHA) is the world's largest, oldest, and most influential voluntary organization dedicated to cardiovascular health. The AHA Scientific Sessions is the world's premier international conference showcasing the latest scientific and clinical advances in cardiovascular disease, brain health, and related conditions. Experts and scholars in the global cardiovascular field will gather to discuss the latest research findings and future treatment directions.
Mr. Liang Lü, Chairman and General Manager of Huadong Medicine, commented, "We are remarkably encouraged that the Phase 2 clinical results for DR10624 have been selected as Late-Breaking Science at AHA 2025 and will be presented globally as the Opening Presentation. This not only highlights the outstanding innovation capabilities of Huadong Medicine and Doer Bio in drug development for metabolic and cardiovascular diseases but also represents a significant milestone in the history of China's cardiovascular drug innovation. Huadong Medicine and Doer Bio will continue to deepen our commitment to innovative drug R&D, promoting more China-originated innovative therapies globally to provide patients with superior treatment options!"
Dr. Yanshan Huang, Founder & Chief Executive Officer of Doer Bio, stated, "DR10624 is a first-in-class, long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R. Developed using Doer Bio's proprietary MultipleBody® platform technology, it aims to provide comprehensive metabolic benefits for patients with metabolic diseases. The Phase 2 clinical results for DR10624 being presented on the prestigious international stage of AHA 2025 will powerfully showcase China's voice and innovation in this field."
Dr. Yongliang Fang, Chief Operating Officer of Doer Bio, added, "The public health threat posed by SHTG is receiving increasing attention. SHTG patients face higher risks of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD), conditions that significantly increase the risks of hospitalization and mortality. The Phase 2 clinical results for SHTG presented at AHA 2025 demonstrate that DR10624 has excellent efficacy in lowering triglycerides, comprehensively regulating pro-inflammatory lipid profiles, and rapidly and deeply reducing liver fat. It holds significant promise as a future innovative therapy for SHTG and various cardiovascular diseases."
For more information about the DR10624-201 clinical trial, please visit clinicaltrials.gov (Identifier: NCT06555640).
About Doer Bio
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical-stage biopharmaceutical company focused on discovering and developing multi-domain, multi-specific biologic therapeutics to address unmet medical needs in metabolic diseases and cancer.
Doer Bio has developed several proprietary platform technologies, including xLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody®.
For more information about Doer Bio, please visit www.doerbio.com or contact bd@doerbio.com.